配合物{[Cu(pcba)2]2·(MeOH)2}的合成、结构、HSA结合及细胞毒性

摘要/Abstract

摘要： 以对氯苯甲酸为配体,合成了铜配合物{[Cu(pcba)₂]₂·(MeOH)₂}(pcba =对氯苯甲酸,MeOH=甲醇),经元素分析、IR和X射线单晶衍射表征,该配合物属于三斜晶系,P1空间群,晶胞参数为a=6.591 80(10) Å,b=10.769 0(2) Å,c=12.472 2(2) Å,α=90.198 0(10)°,β=104.076(2)°,γ=99.673(2)°,Z=1,D_c=1.593 mg/m³,F(000)=408, 最终结构残差因子R₁=0.040 0,wR₂=0.114 5。采用紫外和荧光光谱对配合物及其跟人血清蛋白(HSA)相互作用的方式进行研究,结果表明,配合物浓度越大,紫外及荧光强度越低。配合物对HSA的猝灭常数K_sv=5.78×10³ L·mol^-1,猝灭速率常数K_q=5.78×10¹¹ L·mol^-1·s^-1,配合物对HSA的结合常数K_a=1.38×10² L·mol^-1,结合位点数n=0.592。同时,本文研究了{[Cu(pcba)₂]₂·(MeOH)₂}对胃癌细胞A549、宫颈癌细胞Hela、肝癌细胞HepG2和人正常肝细胞LO2的抗增殖能力,发现其对三种癌细胞的增殖抑制效果跟顺铂相当,对人正常肝细胞LO2的毒性比顺铂小。

关键词: 铜(Ⅱ), 配合物, HSA结合, 细胞毒性, 增殖抑制

Abstract: In this paper, a copper complex {[Cu(pcba)₂]₂·(MeOH)₂} (pcba=p-chlorbenzoic acid, MeOH=methanol) was synthesized. The structure of the complex was characterized using elemental analysis, IR and X-ray single crystal diffraction. The complex belongs to triclinic, P1 space group, with a=6.591 80(10) Å, b=10.769 0(2) Å, c=12.472 2(2) Å, α=90.198 0(10)°, β=104.076(2)°, γ=99.673(2)°, Z=1, D_c=1.593 mg/m³, F(000)=408. The final R₁=0.040 0, wR₂=0.114 5. The complex and its interaction with human serum albumin (HSA) were studied by UV-Vis absorption and fluorescence spectroscopy. The higher the concentration of complex, the lower the UV-Vis and fluorescence intensity. The quenching constant (K_sv) of the complex to HSA is 5.78×10³ L·mol^-1, the quenching rate constant (K_q) is 5.78×10¹¹ L·mol^-1·s^-1, the binding constant (K_a) is 1.38×10² L·mol^-1, the number of binding bits (n) is 0.592. And the anti-proliferation abilities of the complex on A549, Hela, HepG2, and LO2 were studied. It was found that the proliferation inhibition effect of the complex is similar to that of cisplatin, and the toxicity to LO2 is less than that of cisplatin.

Key words: copper(II), complex, HSA binding, cytotoxic activity, proliferation inhibition

中图分类号:

O641

曾振芳, 蔡杰慧, 黄秋萍, 庞华钰, 杨达钦, 黄秋婵. 配合物{[Cu(pcba)₂]₂·(MeOH)₂}的合成、结构、HSA结合及细胞毒性[J]. 人工晶体学报, 2023, 52(10): 1850-1857.

ZENG Zhenfang, CAI Jiehui, HUANG Qiuping, PANG Huayu, YANG Daqin, HUANG Qiuchan. Synthesis, Structure, HSA Binding and Cytotoxic Activity of Complex {[Cu(pcba)₂]₂·(MeOH)₂}[J]. JOURNAL OF SYNTHETIC CRYSTALS, 2023, 52(10): 1850-1857.

参考文献

[1] 于燕, 李惠玲. 铜代谢及其相关疾病研究进展[J]. 环境与健康杂志, 2018, 35(3): 272-276.
YU Y, LI H L. Copper metabolism disorders and related diseases: a review of recent studies[J]. Journal of Environment and Health, 2018, 35(3): 272-276 (in Chinese).
[2] PANDYA C, PANICKER R R, SENJALIYA P, et al. Designing and synthesis of phosphine derivatives of Ru₃(CO)₁₂ - Studies on catalytic isomerization of 1-alkenes[J]. Inorganica Chimica Acta, 2021, 518: 120211.
[3] 谢玉玉, 杜睿智, 魏晨燕, 等. 三联吡啶衍生物稀土(镝和镱)配合物的结构和磁性研究[J]. 中国科学: 化学, 2020, 50(9): 1151-1158.
XIE Y Y, DU R Z, WEI C Y, et al. Mononuclear Yb and Dy single molecule magnets based on the terpyridine derivatives[J]. Scientia Sinica (Chimica), 2020, 50(9): 1151-1158 (in Chinese).
[4] STEPANENKO O V, STEPANENKO O V, SHPIRONOK O G, et al. Near-infrared markers based on bacterial phytochromes with phycocyanobilin as a chromophore[J]. International Journal of Molecular Sciences, 2019, 20(23): 6067.
[5] ABU SHAMMA A, ABU ALI H, KAMEL S. Synthesis, characterization and biological properties of mixed ligand complexes of cobalt(II/III) valproate with 2, 9-dimethyl-1, 10-phenanthroline and 1, 10-phenanthroline[J]. Applied Organometallic Chemistry, 2018, 32(1): e3904.
[6] 邵娜, 何永科. 以芳香羧酸配体构筑的Co(Ⅱ)配位聚合物的合成及结构[J]. 云南化工, 2018, 45(10): 146-147.
SHAO N, HE Y K. Synthesis and structure analysis of single crystal of transition metal Co[J]. Yunnan Chemical Technology, 2018, 45(10): 146-147 (in Chinese).
[7] 熊时鹏. 抗肿瘤药物与HSA的相互作用及分子模拟[D]. 上海: 上海师范大学, 2018.
XIONG S P. Interaction between anti-tumor drugs and HSA and its molecular simulation[D].Shanghai: Shanghai Normal University, 2018 (in Chinese).
[8] GROSSMAN S, GRUNNET M, et al. Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: eastern cooperative oncology group trial 2394[J]. Journal of Clinical Oncology, 2003, 21(8): 1485-1491.
[9] LYNCH T J, BONDARENKO I, LUFT A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study[J]. Journal of Clinical Oncology, 2012, 30(17): 2046-2054.
[10] SALTZ L B, CLARKE S, DAZ-RUBIO E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study[J]. Journal of Clinical Oncology, 2008, 26(12): 2013-2019.
[11] JOMAA M Y, ALTAF M, AHMAD S, et al. Synthesis, spectroscopic characterization and in vitro anticancer activity of new platinum(II) complexes with some thione ligands in the presence of triethylphosphine[J]. BioMetals, 2017, 30(5): 787-795.
[12] 朱洁洁, 王华. 铜诱导调节性细胞死亡的作用机制与抗肿瘤治疗的研究进展[J]. 江苏大学学报(医学版), 2022, 32(4): 326-331+349.
ZHU J J, WANG H. Research progress on the mechanism of copper-induced regulatory cell death and anti-tumor therapy[J]. Journal of Jiangsu University (Medicine Edition), 2022, 32(4): 326-331+349 (in Chinese).
[13] SHELDRICK G. SHELX-84: a program system for crystal structure solution and refinement[J]. Acta Crystallographica Section A Foundations of Crystallography, 1984, 40(a1): C440.
[14] ZAREIAN-JAHROMI S, MANSOURI-TORSHIZI H. Synthesis, characterization, DNA and HSA binding studies of isomeric Pd (II) antitumor complexes using spectrophotometry techniques[J]. Journal of Biomolecular Structure and Dynamics, 2018, 36(5): 1329-1350.
[15] ALI YASREBI S, TAKJOO R, RIAZI G H. HSA-interaction studies of uranyl complexes of alkyl substituted isothiosemicarbazone[J]. Journal of Molecular Structure, 2019, 1193: 53-61.
[16] SHAHRAKI S, HEYDARI A, DELARAMI H S, et al. Preparation, characterization and comparison of biological potency in two new Zn(II) and Pd(II) complexes of butanedione monoxime derivatives[J]. Journal of Biomolecular Structure and Dynamics, 2020, 38(4): 997-1011.
[17] MA A Q, CHEN H Q, CUI Y H, et al. Metalloporphyrin complex-based nanosonosensitizers for deep-tissue tumor theranostics by noninvasive sonodynamic therapy[J]. Small, 2019, 15(5): e1804028.
[18] 曾振芳, 袁芳, 黄秋萍, 等. 对氯苯甲酸构筑的铜(Ⅱ)配合物的合成、HSA结合及细胞毒性[J]. 人工晶体学报, 2022, 51(1): 126-131.
ZENG Z F, YUAN F, HUANG Q P, et al. Synthesis, HSA binding, and cytotoxic activity of copper(Ⅱ) complex constructed by P-chlorobenzoic acid[J]. Journal of Synthetic Crystals, 2022, 51(1): 126-131 (in Chinese).
[19] 曾振芳, 蔡杰慧, 黄秋萍, 等. 铜(Ⅱ)配合物{[Cu(OMBA)₂]₂·(DMF)₂}的合成、CT-DNA结合及细胞毒性[J]. 人工晶体学报, 2021, 50(12): 2300-2306+2331.
ZENG Z F, CAI J H, HUANG Q P, et al. Synthesis, CT-DNA binding, and cytotoxic activity of copper(Ⅱ) complex{[Cu(OMBA)₂]₂·(DMF)₂}[J]. Journal of Synthetic Crystals, 2021, 50(12): 2300-2306+2331 (in Chinese).
[20] CHAVES O A, MENEZES L B, IGLESIAS B A. Multiple spectroscopic and theoretical investigation of meso-tetra-(4-pyridyl)porphyrin-ruthenium(II) complexes in HSA-binding studies. Effect of Zn(II) in protein binding[J]. Journal of Molecular Liquids, 2019, 294: 111581.
[21] ABYAR F, TABRIZI L. New multinuclear Scaffold molybdocene-gold lidocaine complex: DNA/HSA binding, molecular docking, cytotoxicity and mechanistic insights[J]. Journal of Biomolecular Structure and Dynamics, 2019, 37(13): 3366-3378.
[22] ZENG Z F, HUANG Q P, CAI J H, et al. Synthesis, characterization, DNA/HSA interactions, and anticancer activity of two novel copper(II) complexes with 4-chloro-3-nitrobenzoic acid ligand[J]. Molecules, 2021, 26(13): 4028.

配合物{[Cu(pcba)₂]₂·(MeOH)₂}的合成、结构、HSA结合及细胞毒性

Synthesis, Structure, HSA Binding and Cytotoxic Activity of Complex {[Cu(pcba)₂]₂·(MeOH)₂}

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	保玉婷, 梁毅农, 孙赞. 一例锶配合物的合成、结构及表征[J]. 人工晶体学报, 2024, 53(2): 293-299.
[2]	祁金阳, 王敏, 杨瑞杰, 张迎春, 宋志国. 一种新型苯磺酸-咪唑配合物的结构及催化性能研究[J]. 人工晶体学报, 2024, 53(2): 300-306.
[3]	钏定泽, 颜廷亭, 刘继涛. 磁性羟基磷灰石晶须的制备及其在磁场下的磁响应行为研究[J]. 人工晶体学报, 2023, 52(8): 1532-1539.
[4]	张银, 于卫东. 配体引导铜基配合物的合成、表征及催化性能[J]. 人工晶体学报, 2023, 52(6): 1145-1153.
[5]	李大鹏, 孙国富, 葛素香. 溶剂热法制备金属酞菁晶体的研究进展[J]. 人工晶体学报, 2023, 52(4): 678-687.
[6]	田娜, 刘英才, 杨远航, 肖晨希, 朱建宇, 段博峰, 张强, 宋娟. 一例吡嗪羧酸镉配合物的合成、结构及荧光性质研究[J]. 人工晶体学报, 2023, 52(2): 322-326.
[7]	王宏胜, 李会, 刘瞻, 梁彩莲. Eu(III)与两种吡啶二甲酸配合物的合成、晶体结构与发光性能[J]. 人工晶体学报, 2023, 52(10): 1829-1835.
[8]	王润宾, 韩天植, 李知敏, 尧智玲, 廖向文, 王金涛. 一种含吗啉修饰的多吡啶钯(Ⅱ)配合物的合成、表征与抗金黄色葡萄球菌作用研究[J]. 人工晶体学报, 2023, 52(10): 1842-1849.
[9]	王洋, 李铭, 关金涛, 张智勇, 闫俊涛, 熊兰, 毛佳伟. 3-甲基吡啶悬臂Cu(II)-Zn(II)异双核配合物的合成、晶体结构及其与CT-DNA的结合活性[J]. 人工晶体学报, 2023, 52(10): 1858-1866.
[10]	黄妙龄, 陈亮莹, 赵俞秉, 谭欣宇, 叶梦月. 4-硝基氮氧化吡啶-2-甲酸构筑的镧、镨配合物的合成、晶体结构及荧光性质[J]. 人工晶体学报, 2023, 52(1): 125-131.
[11]	王洋, 李铭, 吴宇, 闫俊涛, 毛佳伟. 一种新型双吡啶悬臂Mn(Ⅱ)配合物的合成、晶体结构及DNA结合能力研究[J]. 人工晶体学报, 2022, 51(7): 1220-1226.
[12]	王静怡, 张众, 王梓兰, 于鑫颖, 由君颐, 朱君怡, 杨琳. 吡啶鎓盐配体构筑的多钼酸基配合物的合成、结构及光催化性能[J]. 人工晶体学报, 2022, 51(7): 1227-1232.
[13]	秦英恋, 秦建芳. 基于构象灵活的N-杂环配体构筑的3D拟卤化亚铜配合物的合成、结构和性质研究[J]. 人工晶体学报, 2022, 51(6): 1059-1068.
[14]	蔡英, 钏定泽, 陈庆华, 刘继涛. 氨基酸/氧化石墨烯/羟基磷灰石复合材料在酸蚀人牙釉质体外再矿化中的应用[J]. 人工晶体学报, 2022, 51(3): 516-522.
[15]	伍国云, 刘丹, 危冬梅. 一例镉(Ⅱ)配合物的合成、结构与性质[J]. 人工晶体学报, 2022, 51(2): 304-308.